Buradasınız

Osteogenezis imperfekta tedavisinde yenilikler ve pamidronat tedavisi

New therapeutic agents for the treatment of osteogenesis ımperfecta and pamidronate treatment

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Osteogenesis imperfecta (OI) is a genetic disorder that characterized by low bone mass and increased bone fragility. The prevalence of OI is estimated as 1 in 20 000 births. In the majority of cases, diagnosis of OI is easy on the basis of clinical and radiological findings. Physiotherapy, rehabilitation, and orthopaedic sugery are the mainstay of treatment for patients with OI. In this report, we present a newborn who was diagnosed as OI which is a rare disorder in childhood with clinical and laboratory findings such as triangular face, dark sklera and multiple fractures, bone deformities, hyperplastic callus formation on x-rays on postnatal first day of life, to discuss new treatment methods and recent literature.
Abstract (Original Language): 
Osteogenezis imperfekta kemik kitlesinde azalma ve kemik frajilitesinde artma ile karakterize, yaklaşık 20 000 doğumda bir görülen genetik bir bozukluktur. Klinik ve radyolojik bulgular ile tanısı kolay konulabilen hastalığın tedavisi, medikal, fizik tedavi ve rehabilitasyon ile ortopedik cerrahi eşliğinde multidisipliner bir çalışmayı gerektirir. Postnatal birinci gününde; fizik muayenede üçgen yüz, koyu gri sklera, çekilen kemik grafilerinde çoklu kırık, kemik deformiteleri, kallus formasyonu saptanan ve osteogenesis imperfekta tanısı konulan olgu, nadir görülmesi ve tedavideki yenilikleri literatür eşliğinde tartışmak amacıyla sunulmuştur.

REFERENCES

References: 

1. Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. Joint Bone Spine 2005;72:313-8.
2. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363(24):1377-85.
3. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003;88:986-92.
4. Cho TJ, Choi IH, Chung CY, Yoo WJ, Park MS, Park YK. Efficacy of oral alendronate in children with osteogenesis imperfecta. J PediatrOrthop 2005;25:607-12.
5. Marini JC. Osteogenesis imperfecta. In: Behrman RE, Kliegman RM.Jenson HB. (eds). Nelson textbook of pediatrics. (17th ed). Saunders Philadelphia2004;2336-38.
6. Robertson WW. Orthopedics. In: MacDonald MG, Seshia MMK, Mullett MD (eds). Avery's neonatology pathophysiology & management of the newborn. Lippincott Williams & Wilkins Philadelphia 2005:1428¬43.
7. Sillence DO, Senn A, Danks DM. Genetic heterogenity in osteogenesis imperfecta. J Med Genet 1979;16:101-
16.
8. Vyskocil V, Pikner R, Kutilek S. Effect ofalendronate therapy in children with osteogenesis imperfecta Joint Bone Spine 2005;72:416-23.
9. Chien YH, Chu SY, Hsu CC, Hwu WL. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 2002;25:593-95.
10. Millington-Ward S, McMahon HP, Farrar GJ. Emerging therapeutic approaches for
osteogenesis imperfecta. Trends in Molecular Medicine 2005;11(6):299-305.
11. Whyte MP. Osteogenesis imperfecta. In: Favus MJ (editor). Primer on the metabolic bone diseases and disorders ofmineral metabolisms. (4th ed). Lippincott Williams & Wilkins Philadelphia 1999:386-89.
12. Devogelaer JP, Malghem J, Maldague B, Nagant dD. Radiological manifestations of bisphosphonate treatment with ADP in a child suffering from osteogenesisimperfecta. SkeletalRadiol 1987;16:360-
63.
13. Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta typeV.Bone2005:1-8.
14. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-50.
15. Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, Rogol AD, Wilson TA. Bisphosphonate treatment ofpediatric bone disease. Ped. Endocrinol. Rev. 2005;2:87-96.

Thank you for copying data from http://www.arastirmax.com